Last reviewed · How we verify
RYZ101
RYZ101 is a small molecule that targets the SGLT2 receptor.
RYZ101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | RYZ101 |
|---|---|
| Sponsor | RayzeBio, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, RYZ101 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
Key clinical trials
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. (PHASE1, PHASE2)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma (PHASE1, PHASE2)
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (PHASE1)
- A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RYZ101 CI brief — competitive landscape report
- RYZ101 updates RSS · CI watch RSS
- RayzeBio, Inc. portfolio CI